Avesta Ketamine and Wellness is Opening a Second Location in McLean Virginia November 2020

Share Article

Avesta Ketamine and Wellness is excited to announce the opening of their second location in McLean Virginia November 2020. Avesta Ketamine and Wellness is a provider of IV Ketamine Infusions for the treatment of depression, anxiety, PTSD, migraines, fibromyalgia, and chronic pain. They are also a provider of IV Vitamin Infusions for health and wellness.

Dr. Ladan Eshkevari

Dr. Ladan Eshkevari

Many patients who are struggling with treatment resistant depression, PTSD or anxiety find real relief and new hope with ketamine treatments. In today’s anxiety-stricken environment is more important than ever for people to be able to get the help they need--and get real relief.

Avesta Ketamine and Wellness is excited to announce the opening of their second location in McLean Virginia November 2020. Avesta Ketamine and Wellness is a provider of IV Ketamine Infusions for the treatment of depression, anxiety, PTSD, migraines, fibromyalgia, and chronic pain. They are also a provider of IV Vitamin Infusions for health and wellness.

About Dr. Ladan Eshkevari, PhD, CRNA, FAAN
Dr. Ladan Eshkevari is the lead clinician at Avesta Ketamine and Wellness and Program Director and Associate Professor in the Doctor of Nurse Anesthesia Practice program at Georgetown University. An award-winning provider, Dr. Eshkevari is an expert in the areas of anesthesia, pain management, and alternative medicine, specializing in central and peripheral mechanisms of pain and stress responses. Dr. Eshkevari has been published in numerous journals, including Experimental Biology and Medicine, and Endocrinology. Her research has stimulated international interest in her work, which has been highlighted in numerous popular magazines such as National Geographic, Time Magazine and on NPR Boston. She was recently inducted as a Fellow in the American Academy of Nursing, the highest honor bestowed on nurses both nationally, and internationally. Known for her compassionate bedside manner, high-level of professionalism, and individualized approach, Dr. Eshkevari is a pioneer in her field.

About Ketamine Infusions For Depression, Anxiety, PTSD
A faithful advocate, Dr. Eshkevari explains, “You may have heard that Ketamine is available for the treatment of mood disorders such as major depression, PTSD, anxiety as well as chronic pain, but beyond that you may not know much more. Many patients who are struggling with treatment resistant depression, PTSD or anxiety find real relief and new hope with ketamine treatments. In today’s anxiety-stricken environment is more important than ever for people to be able to get the help they need--and get real relief. I encourage everyone to get the facts about Ketamine.”

Understanding Ketamine
The World Health Organization (WHO) deems, “Ketamine [is] one of the most essential medications due to its therapeutic effects and wide margin of safety.” Developed in the 1960s and approved for use in the United States in 1970, Ketamine works by inducing both hypnotic (sleep-inducing) and analgesic (pain-relieving) effects. Ketamine is deemed a complete anesthetic with minimal effects on cardiovascular function, respiratory drive, and airway reflexes. It is used extensively for pediatric and adult treatment in surgery, emergency departments, trauma medicine, and war zones.”

How Ketamine Works
Dr. Eshkevari explains, “Ketamine works on several brain areas involved in symptoms of depression, anxiety, suicidal ideation, obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), postpartum depression (PPD), and numerous pain syndromes. It helps with shuttling needed neurotransmitters to where they are depleted, and has been shown to grow new neuronal connections in animal models of depression and anxiety.” In fact she says, “In the last decade, there has been mounting evidence that up to 80% of patients suffering from treatment-resistant depression have benefited from Ketamine infusions.”

Are Ketamine Infusions Safe?
Ketamine IV infusion treatments for mood disorders and chronic pain are very safe when administered by clinicians like highly trained anesthesia providers with board certifications. Additionally, Ketamine has a strong body of evidence-based research supporting its use. In fact, numerous certified registered nurse anesthetists (CRNAs) have conducted extensive research on stress and impacts on the brain including depression and anxiety and have found ketamine to be highly effective, therapeutic, and non-addictive, which are three of the most critical factors supporting its clinical use for mood disorders and chronic pain.

Who is the ideal candidate for Ketamine Infusions?
Dr. Eshkevari notes, “The ideal candidate is typically a patient that has tried other forms of treatment without success and/or has been diagnosed as treatment resistant. Ketamine can often be the difference in a patient resuming a normal and healthy lifestyle, which usually they had not thought possible because of a history of successive treatment failures. For many, ketamine IV infusion treatments restore hope.”

The facts about Ketamine

  • Patients cannot administer IV Ketamine or Esketamine (Spravato) themselves
  • Unlike opioids, Ketamine is physically non-addictive
  • Patients must demonstrate a clinical need
  • IV Ketamine, and Spravato Ketamine are only available at a certified doctor’s office or clinic

Their newest McLean office is located at 6861 Elm Street, Suite 3E McLean, Virginia 22101. If you would like to learn more about Avesta Ketamine and Wellness, please visit http://www.avestaketaminewellness.com or call 703-201-7767. Also, follow them on Facebook page @avestaketaminewellness for updates, tips, ideas and more.

References
Thirty-sixth WHO Expert Committee on Drug Dependence agenda item 6.2. Letter from the World Society of Intravenous Anaesthesia to the WHO Expert Committee on Drug Dependence. Geneva, WHO, 2014

Tiger, M., Veldman, E.R., Ekman, C. et al. A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Transl Psychiatry 10, 159 (2020). https://doi.org/10.1038/s41398-020-0844-4

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ladan Eshkevari
Visit website